ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Creatine for the Treatment of Amyotrophic Lateral Sclerosis

This study has been completed.

Sponsors and Collaborators: National Center for Complementary and Alternative Medicine (NCCAM)
Office of Dietary Supplements (ODS)
Information provided by: National Center for Complementary and Alternative Medicine (NCCAM)
ClinicalTrials.gov Identifier: NCT00070993
  Purpose

Creatine is a naturally occurring chemical involved in the production of energy in muscle. Abnormalities in creatine have been linked to the progression of degenerative neuromuscular diseases such as amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). This study will test whether taking creatine can improve the symptoms of ALS.


Condition Intervention Phase
Amyotrophic Lateral Sclerosis
Drug: creatine monohydrate
Phase II

Genetics Home Reference related topics:   amyotrophic lateral sclerosis   

MedlinePlus related topics:   Amyotrophic Lateral Sclerosis   

ChemIDplus related topics:   Creatine    Creatine monohydrate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Efficacy Study
Official Title:   Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis

Further study details as provided by National Center for Complementary and Alternative Medicine (NCCAM):

Estimated Enrollment:   110
Study Start Date:   December 2002
Estimated Study Completion Date:   May 2006

Detailed Description:

Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder selectively affecting motor neurons, resulting in progressive weakness. Currently there is no known cure and a specific cause has not been identified. Creatine is a nutritional supplement that improves mitochondrial function and has been shown to protect motor neurons in animal models of ALS. Preliminary research indicates that creatine may also improve strength in patients with ALS. This study will determine the effect of creatine treatment on short-term muscle strength and long-term muscle deterioration in patients with ALS.

Participants in this study will be randomly assigned to receive either creatine or placebo. Participants will be enrolled in the study for 9 months. Quantitative muscle testing will be done weekly for the first 3 weeks; participants will then be followed monthly for the next 4 months and bimonthly for the remainder of the 9-month study. The study will also monitor purposeful exercise to determine if this enhances the benefit of creatine usage on muscle strength. Pulmonary function testing will accompany the muscle testing to determine if creatine strengthens respiratory muscles, thereby enhancing pulmonary function.

  Eligibility
Ages Eligible for Study:   21 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria

  • Diagnosis of probable or definite ALS
  • At least 5 of 10 testable upper extremity muscle groups (shoulder and elbow extensors/flexors and grip) of Medical Research Council (MRC) grade 4 or better
  • At least 5 years from onset of symptoms

Exclusion Criteria

  • Requires tracheostomy ventilation
  • History of renal disease
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00070993

Locations
United States, California
California Pacific Medical Center    
      San Francisco, California, United States, 94115
United States, Illinois
Rush-Presbyterian St. Luke's Medical Center    
      Chicago, Illinois, United States, 60612
United States, Kansas
University of Kansas Medical Center    
      Kansas City, Kansas, United States, 66160
United States, New Mexico
University of New Mexico - Medical Center    
      Albuquerque, New Mexico, United States, 87131
United States, Texas
University of Texas Health and Science Center    
      San Antonio, Texas, United States, 78284
United States, Virginia
University of Virginia Health System    
      Charlottesville, Virginia, United States, 22908

Sponsors and Collaborators

Investigators
Principal Investigator:     Jeffrey Rosenfeld, MD     Carolinas Medical Center    
  More Information

Study ID Numbers:   R01 AT000967-01
First Received:   October 9, 2003
Last Updated:   August 3, 2006
ClinicalTrials.gov Identifier:   NCT00070993
Health Authority:   United States: Food and Drug Administration

Keywords provided by National Center for Complementary and Alternative Medicine (NCCAM):
ALS  
Creatine  

Study placed in the following topic categories:
Amyotrophic lateral sclerosis
Neuromuscular Diseases
Spinal Cord Diseases
Amyotrophic Lateral Sclerosis
Central Nervous System Diseases
Lou Gehrig's disease
Sclerosis
Degenerative motor system disease
Neurodegenerative Diseases
Motor neuron disease
Motor Neuron Disease

Additional relevant MeSH terms:
Pathologic Processes
Nervous System Diseases

ClinicalTrials.gov processed this record on August 21, 2008




Links to all studies - primarily for crawlers